12/17/2012
Aposense Completes Phase 2 Trial with ML-10, its Novel Apoptosis PET Agent for Imaging Early Response to Treatment of Brain Metastases and Reports Top-Line Results
Read More
|
9/5/2011
Aposense Cancer Drug Demonstrates 100% Oral Bioavailability in New Study
Read More
|
8/11/2010
Roche to Use Aposense EarliTest™ for Imaging of Apoptosis in Oncology Clinical Trials
Read More
|
9/6/2010
Aposense Announces Successful Completion of IPO
- Company Raises over US $24 Million in IPO and Concurrent Private Placement -
- Deal Values Aposense at Over US $230 Million Post-IPO -
Read More
|
9/21/2009
IBA and Aposense Sign Strategic Collaboration to Commercialize Aposense® ML-10 for Molecular Imaging of Apoptosis
Read More
|
6/16/2009
APOSENSE® Imaging agent detects early cell death induced by radiation in patients with brain metastases
Read More
|
12/15/2008
Aposense® Apoptosis Imaging Program for Cancer Therapy Monitoring Initiates a Phase II Multi-Center Study at Memorial Sloan-Kettering Cancer Center
Read More
|
9/2/2008
Aposense® [18F]-ML-10 to be Radiolabelled by IBA for Multi-Center Clinical Trials
Read More
|
9/1/2008
Aposense® Raise Funds and Change Name
Read More
|
7/23/2008
Aposense® [18F]-ML-10 for Molecular Imaging of Apoptosis to Proceed to Phase I/II Trials
Read More
|
11/3/2008
Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo
Read More
|